JP2013514980A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514980A5
JP2013514980A5 JP2012544854A JP2012544854A JP2013514980A5 JP 2013514980 A5 JP2013514980 A5 JP 2013514980A5 JP 2012544854 A JP2012544854 A JP 2012544854A JP 2012544854 A JP2012544854 A JP 2012544854A JP 2013514980 A5 JP2013514980 A5 JP 2013514980A5
Authority
JP
Japan
Prior art keywords
compound according
group
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514980A (ja
JP5922031B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060862 external-priority patent/WO2011084642A1/en
Publication of JP2013514980A publication Critical patent/JP2013514980A/ja
Publication of JP2013514980A5 publication Critical patent/JP2013514980A5/ja
Application granted granted Critical
Publication of JP5922031B2 publication Critical patent/JP5922031B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544854A 2009-12-16 2010-12-16 化合物 Expired - Fee Related JP5922031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28708209P 2009-12-16 2009-12-16
US61/287,082 2009-12-16
PCT/US2010/060862 WO2011084642A1 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015218140A Division JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Publications (3)

Publication Number Publication Date
JP2013514980A JP2013514980A (ja) 2013-05-02
JP2013514980A5 true JP2013514980A5 (enExample) 2014-02-13
JP5922031B2 JP5922031B2 (ja) 2016-05-24

Family

ID=43629477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012544854A Expired - Fee Related JP5922031B2 (ja) 2009-12-16 2010-12-16 化合物
JP2015218140A Withdrawn JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015218140A Withdrawn JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Country Status (12)

Country Link
US (2) US8846682B2 (enExample)
EP (1) EP2513090A1 (enExample)
JP (2) JP5922031B2 (enExample)
KR (1) KR20120112548A (enExample)
CN (1) CN102725284A (enExample)
AU (1) AU2010339841B2 (enExample)
BR (1) BR112012014807A2 (enExample)
CA (1) CA2784744A1 (enExample)
MX (1) MX335989B (enExample)
NZ (1) NZ600449A (enExample)
RU (1) RU2012129882A (enExample)
WO (1) WO2011084642A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631388A (en) 2012-03-28 2016-01-29 Neuropore Therapies Inc Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
EP2872143B1 (en) * 2012-07-16 2017-12-13 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
WO2014179303A1 (en) * 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
CA2937967C (en) 2014-01-29 2022-07-26 Neuropore Therapies, Inc. Heteroaryl amides as inhibitors of protein aggregation
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011931A2 (pt) 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de alcóxi bis-heteroarila como moduladores da agregação de proteína
ES2884145T3 (es) * 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
ES2882285T3 (es) * 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
EP3634407A1 (en) 2017-05-11 2020-04-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
EA201992397A1 (ru) 2017-05-11 2020-03-16 Реминд Н.В. Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
US20250074902A1 (en) * 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
TW202412787A (zh) 2022-07-29 2024-04-01 日商住友製藥股份有限公司 2(1h)-吡啶亞胺衍生物
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof
CN121487929A (zh) * 2023-06-25 2026-02-06 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726263A3 (en) * 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
US5591695A (en) * 1995-02-08 1997-01-07 American Cyanamid Co. Herbicidal [1,3,4]oxadiazoles and thiadiazoles
JP2001505585A (ja) * 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6096688A (en) * 1996-12-27 2000-08-01 American Cyanamid Company Oxazole carboxamide herbicides
EP1708697A4 (en) 2004-01-30 2007-11-28 Smithkline Beecham Corp CHEMICAL COMPOUNDS
NZ554545A (en) * 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
EP2276726A1 (en) * 2008-04-18 2011-01-26 University of Connecticut Compounds for lysosomal modulation and methods of use
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2013514980A5 (enExample)
JP2013510120A5 (enExample)
JP2014500861A5 (enExample)
JP2010077141A5 (enExample)
JP2013542247A5 (enExample)
JP2010524932A5 (enExample)
JP2013510178A5 (enExample)
JP2014506907A5 (enExample)
JP2015537020A5 (enExample)
JP2009504764A5 (enExample)
JP2017533968A5 (enExample)
JP2013544276A5 (enExample)
JP2006524660A5 (enExample)
JP2011528658A5 (enExample)
JP2011507896A5 (enExample)
JP2012513416A5 (enExample)
JP2014508804A5 (enExample)
WO2009095872A3 (en) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
PH12013501442B1 (en) Immunosuppressant formulations
JP2012512863A5 (enExample)
JP2013542981A5 (enExample)
JP2015509075A5 (enExample)
JP2011509302A5 (enExample)
JP2003503449A5 (enExample)
JP2013518036A5 (enExample)